Literature DB >> 3365526

Therapeutic intervention in rheumatoid arthritis: a case-controlled comparison of seronegative and seropositive disease.

P A Reilly1, J Elswood, A Calin.   

Abstract

The records of 684 patients with rheumatoid arthritis (RA) attending a referral centre were evaluated. All available patients (62 cases) with definite seronegative disease were matched, where possible, for sex, age and year of onset with seropositive controls (54 cases). Seronegative females were just as likely as those who were seropositive to require treatment with disease-modifying antirheumatic drugs, whereas seronegative males were significantly less likely to do so than seropositive controls. There were no major differences in outcome or drug toxicity. Orthopaedic surgery was equally common in the two groups, with a similar spectrum of procedures, but there was a trend towards more frequent upper limb large joint arthroplasty in the seronegative group, and this was particularly evident when elbow prostheses were considered. Seronegative rheumatoid disease (at least in females) may be as severe as seropositive disease in a referral-centre population and should be treated with similar vigour.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3365526     DOI: 10.1093/rheumatology/27.2.102

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  3 in total

Review 1.  Prognostic factors of severe rheumatoid arthritis.

Authors:  R Westhovens
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

Review 2.  Prognostic markers in rheumatoid arthritis and classification of antirheumatic therapies.

Authors:  E H Choy; D L Scott
Journal:  Drugs       Date:  1995       Impact factor: 9.546

3.  A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis.

Authors:  M Farr; L Waterhouse; A E Johnson; G D Kitas; R W Jubb; P A Bacon
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.